TriPoint Global Research Updates Investment Opinion on China Pharmaceuticals, Inc.

HENDERSON, Nev.--(BUSINESS WIRE)--TriPoint Global Research publishes Update Research Report by Senior Analyst Stanley Ng, on China Pharmaceuticals, Inc. (OTCBB: CFMI)

• Industry: Pharmaceuticals & Biotechnology
• Current Rating: Market Outperform
• Rating Assigned: 7/12/10
• Analyst: Stanley Ng

A 15-page Update Research Report is available for download at http://www.tripointglobalresearch.com/current-research.php, as well as other leading financial portals, that include Reuters, Capital IQ and Research Direct on Bloomberg terminals by entering TRPN.

About China Pharmaceuticals, Inc. (CFMI) (OTCBB: CFMI)

China Pharmaceuticals, Inc. (OTCBB: CFMI), through its wholly owned subsidiary, Xi’an Qinba Pharmaceutical Co. Ltd., is principally engaged in the manufacturing, marketing and sales of a variety of traditional Chinese medicines (TCM) and Western drugs in China.

About TriPoint Global Research, LLC:

TriPoint Global Research, LLC is an independent investment research firm. Its senior analysts are primarily CFAs, and have expertise in many industries. A TriPoint Global Research, LLC research report or note is not intended as an offering or a solicitation of an offer to buy or sell the securities mentioned or discussed. Neither the firm, its principals nor the assigned analysts own or trade shares of any company covered. The firm does not accept any equity compensation. Anyone may enroll a company for research coverage, which currently costs US $30,000 prepaid for three research reports, typically published quarterly, and requisite research notes. TriPoint Global Research, LLC received $30,000 from the company for three research reports with coverage commencing on October 17, 2009.